These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 32991141)

  • 1. Focus on Human Monoamine Transporter Selectivity. New Human DAT and NET Models, Experimental Validation, and SERT Affinity Exploration.
    Ortore G; Orlandini E; Betti L; Giannaccini G; Mazzoni MR; Camodeca C; Nencetti S
    ACS Chem Neurosci; 2020 Oct; 11(20):3214-3232. PubMed ID: 32991141
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design and synthesis of promiscuous high-affinity monoamine transporter ligands: unraveling transporter selectivity.
    Greiner E; Boos TL; Prisinzano TE; De Martino MG; Zeglis B; Dersch CM; Marcus J; Partilla JS; Rothman RB; Jacobson AE; Rice KC
    J Med Chem; 2006 Mar; 49(5):1766-72. PubMed ID: 16509591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monoamine transporter contributions to l-DOPA effects in hemi-parkinsonian rats.
    Conti MM; Meadows SM; Melikhov-Sosin M; Lindenbach D; Hallmark J; Werner DF; Bishop C
    Neuropharmacology; 2016 Nov; 110(Pt A):125-134. PubMed ID: 27452719
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 2-Aminoindan and its ring-substituted derivatives interact with plasma membrane monoamine transporters and α
    Halberstadt AL; Brandt SD; Walther D; Baumann MH
    Psychopharmacology (Berl); 2019 Mar; 236(3):989-999. PubMed ID: 30904940
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Pharmacological Profile of Second Generation Pyrovalerone Cathinones and Related Cathinone Derivative.
    Kolaczynska KE; Thomann J; Hoener MC; Liechti ME
    Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34361040
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Further structure-activity relationship studies of piperidine-based monoamine transporter inhibitors: effects of piperidine ring stereochemistry on potency. Identification of norepinephrine transporter selective ligands and broad-spectrum transporter inhibitors.
    He R; Kurome T; Giberson KM; Johnson KM; Kozikowski AP
    J Med Chem; 2005 Dec; 48(25):7970-9. PubMed ID: 16335921
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Further structural exploration of trisubstituted asymmetric pyran derivatives (2S,4R,5R)-2-benzhydryl-5-benzylamino-tetrahydropyran-4-ol and their corresponding disubstituted (3S,6S) pyran derivatives: a proposed pharmacophore model for high-affinity interaction with the dopamine, serotonin, and norepinephrine transporters.
    Zhang S; Fernandez F; Hazeldine S; Deschamps J; Zhen J; Reith ME; Dutta AK
    J Med Chem; 2006 Jul; 49(14):4239-47. PubMed ID: 16821783
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular determinants for selective recognition of antidepressants in the human serotonin and norepinephrine transporters.
    Andersen J; Stuhr-Hansen N; Zachariassen L; Toubro S; Hansen SM; Eildal JN; Bond AD; Bøgesø KP; Bang-Andersen B; Kristensen AS; Strømgaard K
    Proc Natl Acad Sci U S A; 2011 Jul; 108(29):12137-42. PubMed ID: 21730142
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the monoamine transporters from human and mouse in their sensitivities to psychostimulant drugs.
    Han DD; Gu HH
    BMC Pharmacol; 2006 Mar; 6():6. PubMed ID: 16515684
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Further studies on conformationally constrained tricyclic tropane analogues and their uptake inhibition at monoamine transporter sites: synthesis of (Z)-9-(substituted arylmethylene)-7-azatricyclo[4.3.1.0(3,7)]decanes as a novel class of serotonin transporter inhibitors.
    Zhang A; Zhou G; Hoepping A; Mukhopadhyaya J; Johnson KM; Zhang M; Kozikowski AP
    J Med Chem; 2002 Apr; 45(9):1930-41. PubMed ID: 11960503
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MDMA (Ecstasy) and human dopamine, norepinephrine, and serotonin transporters: implications for MDMA-induced neurotoxicity and treatment.
    Verrico CD; Miller GM; Madras BK
    Psychopharmacology (Berl); 2007 Jan; 189(4):489-503. PubMed ID: 16220332
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular mechanism of citalopram and cocaine interactions with neurotransmitter transporters.
    Ravna AW; Sylte I; Dahl SG
    J Pharmacol Exp Ther; 2003 Oct; 307(1):34-41. PubMed ID: 12944499
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro and in vivo pharmacological characterization of dasotraline, a dual dopamine and norepinephrine transporter inhibitor in vivo.
    Schreiber R; Campbell U; Quinton MS; Hardy LW; Fang QK; Lew R
    Biomed Pharmacother; 2022 Sep; 153():113359. PubMed ID: 35785702
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative modeling of the human monoamine transporters: similarities in substrate binding.
    Koldsø H; Christiansen AB; Sinning S; Schiøtt B
    ACS Chem Neurosci; 2013 Feb; 4(2):295-309. PubMed ID: 23421681
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Substituted methcathinones differ in transporter and receptor interactions.
    Eshleman AJ; Wolfrum KM; Hatfield MG; Johnson RA; Murphy KV; Janowsky A
    Biochem Pharmacol; 2013 Jun; 85(12):1803-15. PubMed ID: 23583454
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The profile of mephedrone on human monoamine transporters differs from 3,4-methylenedioxymethamphetamine primarily by lower potency at the vesicular monoamine transporter.
    Pifl C; Reither H; Hornykiewicz O
    Eur J Pharmacol; 2015 May; 755():119-26. PubMed ID: 25771452
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Further structure-activity relationship studies on 8-substituted-3-[2-(diarylmethoxyethylidenyl)]-8-azabicyclo[3.2.1]octane derivatives at monoamine transporters.
    Cararas SA; Izenwasser S; Wade D; Housman A; Verma A; Lomenzo SA; Trudell ML
    Bioorg Med Chem; 2011 Dec; 19(24):7551-8. PubMed ID: 22055716
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Putative drug binding conformations of monoamine transporters.
    Ravna AW; Sylte I; Kristiansen K; Dahl SG
    Bioorg Med Chem; 2006 Feb; 14(3):666-75. PubMed ID: 16216517
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological and behavioral characterization of D-473, an orally active triple reuptake inhibitor targeting dopamine, serotonin and norepinephrine transporters.
    Dutta AK; Santra S; Sharma H; Voshavar C; Xu L; Mabrouk O; Antonio T; Reith ME
    PLoS One; 2014; 9(11):e113420. PubMed ID: 25427177
    [TBL] [Abstract][Full Text] [Related]  

  • 20. α-PPP and its derivatives are selective partial releasers at the human norepinephrine transporter: A pharmacological characterization of interactions between pyrrolidinopropiophenones and high and low affinity monoamine transporters.
    Maier J; Rauter L; Rudin D; Niello M; Holy M; Schmid D; Wilson J; Blough BE; Gannon BM; Murnane KS; Sitte HH
    Neuropharmacology; 2021 Jun; 190():108570. PubMed ID: 33864800
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.